UPI: Promising pancreatic cancer treatment

Media highlights potential new cancer therapy that could be in clinical trials soon

A new multi-drug combination therapy for pancreatic cancer is inching toward clinical trials in humans, according to University of Cincinnati researchers.

The drug compound, called SapC-DOPS, combines chemotherapy with targeted therapy and is capable of killing the cells that cause a number of cancers, including pancreatic cancer, which is notoriously difficult to treat.

"Based on pre-clinical studies, it has the potential to improve pancreatic cancer treatment," Xiaoyang Qi, PhD, a professor of hematology oncology at the University of Cincinnati College of Medicine and member of the UC Cancer Center. Qi is a lead author on the study which was published in the academic journal Molecular Therapy.

Read the full story.

Read the UC news release.

The Cincinnati Enquirer also covered this research.

Featured photo of pancreatic cancer cells courtesy of National Institutes of Health. Credit/Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC

Next Lives Here

The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.

Related Stories

1

Love it or raze it?

February 20, 2026

An architectural magazine covered the demolition of UC's Crosley Tower.

2

Social media linked to student loneliness

February 20, 2026

Inside Higher Education highlighted a new study by the University of Cincinnati that found that college students across the country who spent more time on social media reported feeling more loneliness.